Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 11/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.47 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.46 |
| ▸ | POLD1 | P28340 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498723 | 0.89 | P2RY6 (0.66) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL498724 | 0.89 | P2RY6 (0.66) | P2RY6P2RY2P2RY4DNPH1 | |
| Cyanide SCHEMBL29185235 | 0.86 | P2RY6 (0.63) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL223586 | 0.83 | POLB (0.55) | POLBPOLA1POLD1 | |
| SCHEMBL223587 | 0.83 | POLB (0.55) | POLBPOLA1POLD1 | |
| Water SCHEMBL6421666 | 0.82 | POLB (0.54) | POLBPOLA1POLD1 | |
| Water SCHEMBL6421677 | 0.82 | POLB (0.54) | POLBPOLA1POLD1 | |
| SCHEMBL2609988 | 0.81 | P2RY6 (0.54) | P2RY6P2RY2P2RY4POLBPOLA1 | |
| SCHEMBL13660661 | 0.81 | P2RY6 (0.55) | P2RY6P2RY2P2RY4POLBPOLA1 | |
| SCHEMBL1501320 | 0.80 | DTYMK (0.52) | P2RY6P2RY2P2RY4POLBPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252030-A1 | 5-BROMO-2'-DEOXY-URIDINE LABELED NUCLEOTIDE TRIPHOSPHATES AND NUCLEIC ACID PROBES AND METHODS OF MAKING AND USING THE SAME | Life Technologies Corporation (US) | 2012-10-04 | — | — | US | disclosed |
| US-8163897-B2 | 5-bromo-2′-deoxy-uridine labeled nucleotide triphosphates and nucleic acid probes and methods of making and using the same | APPLIED BIOSYSTEMS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110207920-A1 | 5-BROMO-2'-DEOXY-URIDINE LABELED NUCLEOTIDE TRIPHOSPHATES AND NUCLEIC ACID PROBES AND METHODS OF MAKING AND USING THE SAME | Life Technologies Corporation (US) | 2011-08-25 | — | — | US | disclosed |
| US-7915392-B2 | 5-bromo-2′-deoxy-uridine labeled nucleotide triphosphates and nucleic acid probes and methods of making and using the same | Life Technologies Corporation (US) | 2011-03-29 | — | — | US | disclosed |
| US-20090325158-A1 | 5-Bromo-2'-Deoxy-Uridine Labeled Nucleotide Triphosphates and Nucleic Acid Probes and Methods of Making and Using the Same | APPLERA CORPORATION (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207920-A1 | 5-BROMO-2'-DEOXY-URIDINE LABELED NUCLEOTIDE TRIPHOSPHATES AND NUCLEIC ACID PROBES AND METHODS OF MAKING AND USING THE SAME | DUT, PCNA, TK1 | P2RY6 679/4885P2RY2 725/4885P2RY4 636/4885 |
| US-20090325158-A1 | 5-Bromo-2'-Deoxy-Uridine Labeled Nucleotide Triphosphates and Nucleic Acid Probes and Methods of Making and Using the Same | DUT, PCNA, TK1 | P2RY6 679/4885P2RY2 725/4885P2RY4 636/4885 |
| US-20120252030-A1 | 5-BROMO-2'-DEOXY-URIDINE LABELED NUCLEOTIDE TRIPHOSPHATES AND NUCLEIC ACID PROBES AND METHODS OF MAKING AND USING THE SAME | DUT, PCNA, TK1 | P2RY6 679/4885P2RY2 725/4885P2RY4 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.